NASDAQ:OPGN OpGen Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding OpGen Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.07 +0.04 (+1.97 %) (As of 09/24/2020 12:00 AM ET) Add Compare Share Today's Range$1.90Now: $2.07▼$2.0950-Day Range$2.03MA: $2.33▼$3.3752-Week Range$0.92Now: $2.07▼$8.33Volume1.07 million shsAverage Volume3.73 million shsMarket Capitalization$40.98 millionP/E RatioN/ADividend YieldN/ABeta-0.54 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media OpGen, Inc., a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. The company's products include Acuitas AMR Gene Panel, a vitro diagnostic test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance in urine specimens or bacterial colonies isolated from urine and other body sites; and QuickFISH and PNA FISH products, which are FDA-cleared and CE-marked diagnostic test designed to detect antimicrobial- resistant pathogens. In addition, it offers Acuitas Lighthouse informatics systems, a cloud-based HIPAA compliant informatics offerings, which combine clinical lab test results with patient and hospital information, and provide analytics and insights to enable manage MDROs in the hospital and patient care environment. The company was incorporated in 2001 and is headquartered in Gaithersburg, Maryland.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingOpGen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.00, OpGen has a forecasted upside of 141.5% from its current price of $2.07.Amount of Analyst CoverageOpGen has received no research coverage in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesOpGen has received 282 “outperform” votes. (Add your “outperform” vote.)Underperform VotesOpGen has received 288 “underperform” votes. (Add your “underperform” vote.)Community SentimentOpGen has received 50.53% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about OpGen and other stocks. Vote “Outperform” if you believe OPGN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe OPGN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldOpGen does not currently pay a dividend.Dividend GrowthOpGen does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, OpGen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,910.00 in company stock.Percentage Held by InsidersOnly 0.36% of the stock of OpGen is held by insiders.Percentage Held by InstitutionsOnly 2.12% of the stock of OpGen is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for OpGen are expected to grow in the coming year, from ($1.63) to ($1.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OpGen is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OpGen is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOpGen has a P/B Ratio of 2.69. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.33 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OPGN Previous Symbol CUSIPN/A CIK1293818 Webwww.opgen.com Phone240-813-1260Debt Debt-to-Equity Ratio0.95 Current Ratio1.78 Quick Ratio1.47Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$3.50 million Price / Sales11.71 Cash FlowN/A Price / Cash FlowN/A Book Value$0.77 per share Price / Book2.69Profitability EPS (Most Recent Fiscal Year)($6.90) Net Income$-12,450,000.00 Net Margins-532.22% Return on Equity-181.57% Return on Assets-77.85%Miscellaneous Employees44 Outstanding Shares19,799,000Market Cap$40.98 million Next Earnings Date11/4/2020 (Estimated) OptionableNot Optionable $2.07 +0.04 (+1.97 %) (As of 09/24/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive OPGN News and Ratings via Email Sign-up to receive the latest news and ratings for OPGN and its competitors with MarketBeat's FREE daily newsletter. OpGen (NASDAQ:OPGN) Frequently Asked Questions How has OpGen's stock been impacted by Coronavirus? OpGen's stock was trading at $2.07 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, OPGN stock has increased by 0.0% and is now trading at $2.07. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of OpGen? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OpGen in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for OpGen. When is OpGen's next earnings date? OpGen is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for OpGen. How were OpGen's earnings last quarter? OpGen Inc (NASDAQ:OPGN) released its quarterly earnings results on Wednesday, August, 12th. The medical research company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.02. The medical research company had revenue of $1.19 million for the quarter. OpGen had a negative net margin of 532.22% and a negative return on equity of 181.57%. View OpGen's earnings history. When did OpGen's stock split? How did OpGen's stock split work? OpGen shares reverse split on the morning of Friday, January 19th 2018. The 1-25 reverse split was announced on Wednesday, January 17th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 18th 2018. An investor that had 100 shares of OpGen stock prior to the reverse split would have 4 shares after the split. What guidance has OpGen issued on next quarter's earnings? OpGen issued an update on its second quarter 2020 Pre-Market earnings guidance on Wednesday, July, 15th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.2-1.2 million, compared to the consensus revenue estimate of $1.2 million. What price target have analysts set for OPGN? 1 equities research analysts have issued 1 year price objectives for OpGen's stock. Their forecasts range from $5.00 to $5.00. On average, they expect OpGen's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 141.5% from the stock's current price. View analysts' price targets for OpGen. Are investors shorting OpGen? OpGen saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 2,080,000 shares, an increase of 13.7% from the August 15th total of 1,830,000 shares. Based on an average trading volume of 6,940,000 shares, the short-interest ratio is presently 0.3 days. View OpGen's Short Interest. Who are some of OpGen's key competitors? Some companies that are related to OpGen include Enzo Biochem (ENZ), Celcuity (CELC), Biocept (BIOC), Anpac Bio-Medical Science (ANPC), Miragen Therapeutics (MGEN), Psychemedics (PMD), Avant Diagnostics (AVDX), PotNetwork (POTN), CBA Florida (CBAI), American Shared Hospital Services (AMS), Cancer Genetics (CGIX), First Choice Healthcare Solutions (FCHS), Aeon Global Health (AGHC), ACI Global (ACGJ) and GeneLink (GNLKQ). View all competitors. What other stocks do shareholders of OpGen own? Based on aggregate information from My MarketBeat watchlists, some companies that other OpGen investors own include Anavex Life Sciences (AVXL), Sorrento Therapeutics (SRNE), Energy Transfer LP Unit (ET), Vaxart (VXRT), Nabriva Therapeutics (NBRV), SCYNEXIS (SCYX), Agile Therapeutics (AGRX), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV) and Pfizer (PFE). Who are OpGen's key executives? OpGen's management team includes the following people: Mr. Evan Jones, Chairman & CEO (Age 62)Mr. Timothy C. Dec, CFO & Corp. Sec. (Age 60)Mr. Vadim Sapiro, Chief Information Officer (Age 48)Mr. Michael Farmer, VP of MarketingDr. G. Terrance Walker Ph.D., Sr. VP of R&D (Age 60) When did OpGen IPO? (OPGN) raised $17 million in an IPO on Tuesday, May 5th 2015. The company issued 2,900,000 shares at $5.50-$6.50 per share. Maxim Group acted as the underwriter for the IPO and National Securities was co-manager. What is OpGen's stock symbol? OpGen trades on the NASDAQ under the ticker symbol "OPGN." Who are OpGen's major shareholders? OpGen's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wedbush Securities Inc. (0.25%) and UBS Group AG (0.14%). Company insiders that own OpGen stock include Evan/ Fa Jones and NV In Liquidation Curetis. View institutional ownership trends for OpGen. Which institutional investors are buying OpGen stock? OPGN stock was purchased by a variety of institutional investors in the last quarter, including Wedbush Securities Inc., and UBS Group AG. View insider buying and selling activity for OpGen. How do I buy shares of OpGen? Shares of OPGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is OpGen's stock price today? One share of OPGN stock can currently be purchased for approximately $2.07. How big of a company is OpGen? OpGen has a market capitalization of $40.98 million and generates $3.50 million in revenue each year. The medical research company earns $-12,450,000.00 in net income (profit) each year or ($6.90) on an earnings per share basis. OpGen employs 44 workers across the globe. What is OpGen's official website? The official website for OpGen is www.opgen.com. How can I contact OpGen? OpGen's mailing address is 708 QUINCE ORCHARD ROAD SUITE 205, GAITHERSBURG MD, 20878. The medical research company can be reached via phone at 240-813-1260 or via email at [email protected] This page was last updated on 9/25/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
